CHMP adopts new dose-finding approach

EMA's CHMP officially adopted a statistical and modeling methodology for the analysis of Phase II dose-finding trials that was proposed by Novartis AG (NYSE:NVS; SIX:NOVN). The (see BioCentury Extra, ...